Entrepreneurship in Central and Eastern Europe 2018
DOI: 10.4324/9781315392387-10
|View full text |Cite
|
Sign up to set email alerts
|

The internationalisation of Richter Gedeon, the Hungarian pharmaceutical company, and entrepreneurship in Hungary

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
7
0
1

Year Published

2019
2019
2024
2024

Publication Types

Select...
5
1

Relationship

2
4

Authors

Journals

citations
Cited by 9 publications
(8 citation statements)
references
References 1 publication
0
7
0
1
Order By: Relevance
“…These strategy changes had their consequences on the internationalisation of the firm as well. At present, the company has a very high export/sales ratio, 89%, which never went below 60% in the last two and a half decades and since 2007, it is permanently above 80% (Antalóczy -Sass 2018). In terms of FDI, 13…”
Section: Richter Gedeon Plcmentioning
confidence: 97%
See 3 more Smart Citations
“…These strategy changes had their consequences on the internationalisation of the firm as well. At present, the company has a very high export/sales ratio, 89%, which never went below 60% in the last two and a half decades and since 2007, it is permanently above 80% (Antalóczy -Sass 2018). In terms of FDI, 13…”
Section: Richter Gedeon Plcmentioning
confidence: 97%
“…The main reason for that is that there are no major foreign owners with more than 10% of the shares: the largest foreign owner, Aberdeen Asset Management Plc., a financial investor owns only 9.79% of the shares. Thus, the ownership structure of Richter Gedeon is highly dispersed, and the control is in the hands of the Hungarian management (Antalóczy -Sass 2018). Richter Gedeon defines itself as a "specialty pharma" firm: it concentrates on the dispensation of specialty pharma drugs.…”
Section: Richter Gedeon Plcmentioning
confidence: 99%
See 2 more Smart Citations
“…In Hungary, similarly to the USA or Japan, more than 2 % of the GDP is pharmaceutical spending (Organisation for Economic Co-operation and Development, 2017); over 30 % of all healthcare spending is pharmaceutical spending (Inotai, Csanádi, Harsányi & Németh, 2017). For a country such as Hungary, the development of knowledge-intensive industries relying heavily on research and development can be a sound long-term economic strategy (Antalóczy & Sass, 2018).…”
Section: Introductionmentioning
confidence: 99%